Trials / Unknown
UnknownNCT05193721
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1901 | SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg |
Timeline
- Start date
- 2022-02-10
- Primary completion
- 2024-06-30
- Completion
- 2024-08-31
- First posted
- 2022-01-18
- Last updated
- 2024-03-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05193721. Inclusion in this directory is not an endorsement.